D. Schrama

J. Becker, E. Bröcker, J. Wischhusen, 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

The HSP70 Modulator MAL3-101 Inhibits Merkel Cell Carcinoma

J. Becker, P. Wipf, J. Brodsky, 2014, PloS one.

Investigation of the RB1-SOX2 axis constitutes a tool for viral status determination and diagnosis in Merkel cell carcinoma

D. Schrama, R. Houben, C. Collin, 2022, Virchows Archiv.

Antibody-Based Therapies for Carcinomas

J. Becker, D. Schrama, 2009 .

Biologics in Targeted Cancer Therapy

D. Schrama, J. Becker, 2007 .

Antibody targeted drugs as cancer therapeutics

David Schrama, Jürgen C. Becker, J. Becker, 2006, Nature Reviews Drug Discovery.

Therapeutic efficacy of tumor-targeted IL2 in LTα−/− mice depends on conditioned T cells

J. Becker, D. Schrama, R. Xiang, 2006, Cancer Immunology, Immunotherapy.

Shift from Systemic to Site-Specific Memory by Tumor-Targeted IL-21

Ralph R. Reisfeld, J. Becker, T. Schumacher, 2004, The Journal of Immunology.

Artesunate Affects T Antigen Expression and Survival of Virus-Positive Merkel Cell Carcinoma

J. Becker, D. Schrama, Christian Adam, 2020, Cancers.

High-Level Expression of Wild-Type p53 in Melanoma Cells is Frequently Associated with Inactivity in p53 Reporter Gene Assays

S. Haferkamp, J. Becker, J. Wischhusen, 2011, PloS one.

Circulation and homing of melanoma‐reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte‐derived dendritic cells

J. Becker, L. Pedersen, W. Hohenberger, 2004, International journal of cancer.

Longitudinal Analysis of MART‐1/HLA‐A2‐Reactive T Cells Over the Course of Melanoma Progression

J. Becker, L. Pedersen, D. Schrama, 2003, Scandinavian journal of immunology.

Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients.

J. Becker, L. Pedersen, D. Schrama, 2001, Cancer research.

In situ cytokine therapy: redistribution of clonally expanded T cells

J. Becker, P. Guldberg, D. Schrama, 2001, European Journal of Immunology.

CD28‐mediated costimulation impacts on the differentiation of DC vaccination‐induced T cell responses

J. Becker, D. Schrama, H. Reichardt, 2006, Clinical and experimental immunology.

Homozygous CRISPR/Cas9 Knockout Generated a Novel Functionally Active Exon 1 Skipping XPA Variant in Melanoma Cells

D. Schrama, L. Boeckmann, M. Martens, 2022, International journal of molecular sciences.

Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma

Olga K Afanasiev, J. Becker, M. Cleary, 2014, Cancer Immunology Research.

Cancer esearch oenvironment and Immunology ibodies to Merkel Cell Polyomavirus T Antigen oproteins Reflect Tumor Burden in Merkel R l Carcinoma Patients

D. Galloway, P. Nghiem, D. Schrama, 2010 .

Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions

J. Becker, E. Bröcker, D. Schrama, 2005, Archives of Dermatological Research.

VEGF-A Inhibition as a Potential Therapeutic Approach in Merkel Cell Carcinoma.

D. Schrama, R. Houben, T. Larcher, 2019, The Journal of investigative dermatology.

Overexpression of matrix metalloproteinases, chemokines, and chemokine receptors relevant for metastasis in experimental models not an indication of lymph node metastases in human melanoma.

D. Schrama, J. Becker, H. Starz, 2007, Archives of dermatology.

CD147 Impacts Angiogenesis and Metastasis Formation

J. Becker, D. Schrama, R. Houben, 2009, Cancer investigation.

Identical T-cell receptor transcripts in multiple melanoma metastases.

J. Becker, E. Bröcker, D. Schrama, 2002, Cancer research.

Breaking immunological tolerance to melanocyte differentiation antigens by hypopigmenting agents: a new means for melanoma immunotherapy?

J. Becker, D. Schrama, 2011, The Journal of investigative dermatology.

Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.

B. Schilling, A. Gesierich, P. Schummer, 2017, Acta dermato-venereologica.

Merkel cell polyomavirus-positive Merkel cell carcinoma cells do not require expression of the viral small T antigen.

J. Becker, D. Schrama, S. Hesbacher, 2013, The Journal of investigative dermatology.

Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.

B. Schilling, A. Gesierich, A. Kerstan, 2018, Melanoma research.

Type I and II IFNs inhibit Merkel cell carcinoma via modulation of the Merkel cell polyomavirus T antigens.

J. Becker, D. Schrama, Christian Adam, 2012, Cancer research.

Type I and II interferons inhibit Merkel cell carcinoma via modulation of the Merkel cell polyomavirus T-antigens

J. Becker, D. Schrama, Christian Adam, 2012 .

þ Cells Correspond to the BDCA2 þ Plasmacytoid Dendritic Cells in Human Melanoma Sentinel Nodes

J. Becker, D. Schrama, Christian Adam, 2010 .

Survivin downregulation is not required for T antigen knockdown mediated cell growth inhibition in MCV infected merkel cell carcinoma cells

J. Becker, D. Schrama, S. Hesbacher, 2013, International journal of cancer.

Comparable expression and phosphorylation of the retinoblastoma protein in Merkel cell polyoma virus positive and negative Merkel cell carcinoma

J. Becker, S. Ugurel, D. Schrama, 2010, International journal of cancer.

Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response

D. Schadendorf, J. Becker, S. Ugurel, 2007, Clinical Cancer Research.

Distribution of telomeric (TTAGGG)n sequences in avian chromosomes

M. Schartl, M. Schmid, T. Haaf, 2002, Chromosoma.

Expression of the NKG2D ligand UL16 binding protein‐1 (ULBP‐1) on dendritic cells

J. Becker, E. Bröcker, D. Schrama, 2006, European journal of immunology.

New insights into the molecular biology and targeted therapy of cutaneous T‐cell lymphomas

David Schrama, J. Becker, C. Klemke, 2006, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Distinction of 2 different primary Merkel cell carcinomas in 1 patient by Merkel cell polyomavirus genome analysis.

A. Hauschild, K. Kähler, J. Becker, 2010, Archives of dermatology.

Cytotoxic T cells.

Mads Hald Andersen, David Schrama, J. Becker, 2006, The Journal of investigative dermatology.

Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma.

S. Haferkamp, W. Peitsch, J. Becker, 2011, The Journal of investigative dermatology.

Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO.

I. Berberich, D. Schrama, R. Houben, 2007, The Journal of investigative dermatology.

Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma.

S. Ugurel, D. Schrama, R. Houben, 2006, The Journal of investigative dermatology.

Merkel Cell Polyomavirus: Infection, Genome, Transcripts and Its Role in Development of Merkel Cell Carcinoma

D. Schrama, R. Houben, T. Kervarrec, 2023, Cancers.

Merkel cell polyomavirus-negative -Merkel cell carcinoma originating from in situ squamous cell carcinoma: a keratinocytic tumor with neuroendocrine differentiation.

F. Aubin, D. Schrama, R. Houben, 2021, The Journal of investigative dermatology.

Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas

F. Aubin, T. Gambichler, D. Schrama, 2018, Modern Pathology.

Mouse models for melanoma: a personal perspective

J. Becker, S. Ugurel, D. Schrama, 2010, Experimental dermatology.

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology

D. Schrama, R. Houben, M. Samimi, 2022, Cancers.

BerEP4 positivity in Merkel cell carcinoma: a potential diagnosis pitfall

H. Vié, D. Schrama, R. Houben, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Morphologic and immunophenotypical features distinguishing Merkel cell polyomavirus-positive and negative Merkel cell carcinoma

F. Aubin, T. Gambichler, D. Schrama, 2019, Modern Pathology.

Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma

D. Schadendorf, J. Becker, S. Ugurel, 2018, Clinical Cancer Research.

Activation of the PI3K/AKT Pathway in Merkel Cell Carcinoma

M. Landthaler, C. Hafner, D. Schrama, 2012, PloS one.

Merkel cell carcinoma – pathogenesis, clinical aspects and treatment

D. Schrama, J. C. Becker, Jürgen C. Becker, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Merkel Cell Polyomavirus-Infected Merkel Cell Carcinoma Cells Require Expression of Viral T Antigens (cid:1)

J. Becker, D. Schrama, R. Houben, 2010 .

Molecular pathogenesis of Merkel cell carcinoma

J. Becker, D. Schrama, R. Houben, 2009, Experimental dermatology.

Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations

J. Becker, E. Thiel, D. Schrama, 2008, Journal of Translational Medicine.

T cell receptor repertoire usage in cancer as a surrogate marker for immune responses

J. Becker, D. Schrama, Cathrin Ritter, 2017, Seminars in Immunopathology.

Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells

M. Goebeler, D. Schrama, S. Hesbacher, 2019, Journal of Hematology & Oncology.

Mechanisms of p53 restriction in Merkel cell carcinoma cells are independent of the Merkel cell polyoma virus T antigens.

J. Utikal, S. Haferkamp, W. Peitsch, 2013, The Journal of investigative dermatology.

Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma

J. Becker, S. Ugurel, S. Ferrone, 2017, Scientific Reports.

Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma

J. Becker, Suzie Chen, D. Schrama, 2012, Cancer Immunology, Immunotherapy.

ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma.

D. Schadendorf, J. Becker, S. Ugurel, 2011, The Journal of investigative dermatology.

IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence

S. Haferkamp, J. Becker, G. Mann, 2010, Cell.

by Tumor-Targeted IL-2 Shift from Systemic to Site-Specific Memory

N. Schumacher, Ralph R. Reisfeld, Jürgen C. Becker, 2013 .

Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue

J. Becker, T. Schumacher, D. Schrama, 2007, Cancer Immunology, Immunotherapy.

Targeted Deep Sequencing of Mycosis Fungoides Reveals Intracellular Signaling Pathways Associated with Aggressiveness and Large Cell Transformation

A. Rosenwald, M. Goebeler, D. Schrama, 2021, Cancers.

The identification of patient‐specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild‐type melanomas

B. Schilling, A. Gesierich, A. Rosenwald, 2019, Cancer.

BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report

C. Massone, S. Ugurel, E. Richtig, 2013, The British journal of dermatology.

New therapeutic approaches for solid tumors: Histone deacetylase, methyltransferase and proteasome inhibitors

S. Ugurel, E. Bröcker, D. Schrama, 2006, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Response to Shuda et al.

J. Becker, D. Schrama, S. Hesbacher, 2014, The Journal of investigative dermatology.

Efficient suppression of NRAS-driven melanoma by co-inhibition of ERK1/2 and ERK5 MAPK pathways.

M. Goebeler, Marc Schmidt, D. Schrama, 2020, The Journal of investigative dermatology.

Non-reproducible sequence artifacts in FFPE tissue: an experience report

J. Becker, S. Ugurel, L. Cerroni, 2017, Journal of Cancer Research and Clinical Oncology.

Anti-cancer therapies targeting the tumor stroma

J. Becker, D. Schrama, V. Hofmeister, 2007, Cancer Immunology, Immunotherapy.

Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth.

D. Schrama, S. Hesbacher, Christian Adam, 2021, Cancer letters.

Histogenesis of Merkel Cell Carcinoma: A Comprehensive Review

E. Blanchard, D. Schrama, R. Houben, 2019, Front. Oncol..

Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.

S. Haferkamp, M. Goebeler, D. Schrama, 2016, Cancer letters.

Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients

D. Schrama, C. Vetter-Kauczok, P. thor Straten, 2009, Cancer Immunology, Immunotherapy.

An intact retinoblastoma protein‐binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells

Johannes P. W. Grimm, J. Becker, E. Bröcker, 2012, International journal of cancer.

Merkel cell carcinoma and Merkel cell polyomavirus: evidence for hit-and-run oncogenesis.

Johannes P. W. Grimm, J. Becker, D. Schrama, 2012, The Journal of investigative dermatology.

Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

J. Schelter, M. Cleary, Z. Argényi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cells

S. Haferkamp, C. Scholz, D. Schrama, 2016, Oncotarget.

Merkel cell carcinoma

J. Becker, D. Schrama, R. Houben, 2008, Cellular and Molecular Life Sciences.

Clinical remission of Merkel cell carcinoma after treatment with imatinib.

J. Becker, F. Breier, A. Steiner, 2013, Journal of the American Academy of Dermatology.

Detection of the Merkel cell polyomavirus in the neuroendocrine component of combined Merkel cell carcinoma

F. Aubin, D. Schrama, R. Houben, 2018, Virchows Archiv.

T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors

J. Becker, S. Hadrup, P. Nghiem, 2014, Clinical Cancer Research.

Merkel Cell Polyomavirus Large T Antigen is Dispensable in G2 and M-Phase to Promote Proliferation of Merkel Cell Carcinoma Cells

D. Schrama, S. Hesbacher, R. Houben, 2020, Viruses.

Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma

David Schrama, Jürgen C. Becker, Paul Nghiem, 2016, Scientific Reports.

P‐cadherin expression in Merkel cell carcinomas is associated with prolonged recurrence‐free survival

W. Peitsch, S. Goerdt, P. Helmbold, 2012, The British journal of dermatology.

No evidence for association of HPyV6 or HPyV7 with different skin cancers.

J. Becker, D. Schrama, R. Houben, 2012, The Journal of investigative dermatology.

Genetic evidence of a sarcomatoid transformation in Merkel cell carcinoma

D. Schrama, R. Houben, R. Appay, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations.

J. Becker, S. Ugurel, L. Cerroni, 2014, JAMA dermatology.

MCPyV Large T antigen induced atonal homolog 1 (ATOH1) is a lineage-dependency oncogene in Merkel cell carcinoma.

J. Becker, T. Gambichler, U. Moens, 2020, The Journal of investigative dermatology.

Highly Expressed miR-375 is not an Intracellular Oncogene in Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma

D. Schrama, J. Becker, A. Zebisch, 2019, bioRxiv.

[Kinase inhibitors for the therapy of malignant melanoma].

J. Becker, E. Bröcker, D. Schrama, 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

The Presence of Polyomavirus in Non-Melanoma Skin Cancer in Organ Transplant Recipients Is Rare

I. Binet, D. Schrama, A. Egli, 2009 .

T-cell clonotypes in cancer

J. Becker, D. Schrama, P. thor Straten, 2004, Journal of Translational Medicine.

Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells.

J. Becker, L. Pedersen, E. Bröcker, 2002, The Journal of investigative dermatology.

Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma

J. Becker, S. Ugurel, E. Bröcker, 2012, Cancer Immunology, Immunotherapy.

Characterization of mouse MAGE‐derived H‐2Kb‐restricted CTL epitopes

J. Becker, D. Schrama, H. Voigt, 2004, European journal of immunology.

Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.

J. Becker, E. Bröcker, W. Fischer, 2001, Immunity.

Immunological consequences of the sentinel lymph-node biopsy--lessons from a melanoma patient.

J. Becker, L. Pedersen, E. Bröcker, 2003, The Lancet. Oncology.

Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients

J. Becker, S. Ugurel, Rajiv Kumar, 2016, Journal of Cancer Research and Clinical Oncology.

Cancer treatment: the combination of vaccination with other therapies

J. Becker, I. Svane, D. Schrama, 2008, Cancer Immunology, Immunotherapy.

Differential expression of CD28 and CD94 / NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node

J. Becker, E. Bröcker, D. Schrama, 2000, European journal of immunology.

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

D. Schadendorf, J. Becker, S. Ugurel, 2008, Cancer Immunology, Immunotherapy.

Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes

J. Becker, P. Guldberg, L. Pedersen, 2006, Cancer Immunology, Immunotherapy.

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients

D. Schadendorf, J. Becker, S. Ugurel, 2014, Front. Med..

Strategies to optimize the use of targeted agents for tumor therapy

J. Becker, S. Ugurel, D. Schrama, 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

CD7(-) T cells are late memory cells generated from CD7(+) T cells.

J. Becker, A. Schmidt, D. Schrama, 2008, Rejuvenation research.

Recurrent FOXK1::GRHL and GPS2::GRHL fusions in trichogerminoma

F. Tirode, T. Jouary, D. Schrama, 2022, The Journal of pathology.

Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53

D. Schadendorf, J. Becker, S. Ugurel, 2020, Oncogene.

Basic Pathobiology of Merkel Cell Carcinoma

J. Becker, D. Schrama, R. Houben, 2010 .

Interaction of transcription factor FoxO3 with histone acetyltransferase complex subunit TRRAP modulates gene expression and apoptosis

M. Goebeler, Marc Schmidt, D. Schrama, 2022, The Journal of biological chemistry.

Molecularly targeted therapy for melanoma

A. Hauschild, J. Becker, R. Dummer, 2006, Cancer.

Oligoclonal CD4+ T Cells Promote Host Memory Immune Responses to Zwitterionic Polysaccharide of Streptococcus pneumoniae

J. Becker, D. Schrama, M. Fabri, 2009, Infection and Immunity.

Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway

S. Fröhling, V. Glutsch, A. Rosenwald, 2021, The British journal of dermatology.

Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1‐deficient skin carcinoma

F. Tirode, D. Schrama, R. Houben, 2023, Histopathology.

P29. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish Merkel cell carcinoma patients from healthy donors

P. Nghiem, D. Schrama, O. Met, 2014, Journal of Immunotherapy for Cancer.

4-[(5-Methyl-1H-pyrazol-3-yl)amino]-2H-phenyl-1-phthalazinone Inhibits MCPyV T Antigen Expression in Merkel Cell Carcinoma Independent of Aurora Kinase A

D. Schrama, S. Hesbacher, Christian Adam, 2023, Cancers.

Control of central and peripheral tolerance to melanocyte differentiation antigens by GILT.

J. Becker, D. Schrama, 2012, The Journal of investigative dermatology.

Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real‐time polymerase chain reaction

A. Rosenwald, D. Schrama, R. Houben, 2021, Journal of cutaneous pathology.

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion

G. Lenz, S. Dunn, D. Schrama, 2023, Journal of Experimental & Clinical Cancer Research.

Distinct regulation of EZH2 and its repressive H3K27me3 mark in Polyomavirus -positive and -negative Merkel cell carcinoma.

P. Peixoto, É. Coyaud, D. Schrama, 2023, The Journal of investigative dermatology.

Gene fusions in poroma, porocarcinoma and related adnexal skin tumours: An update

F. Tirode, A. Barlier, D. Schrama, 2023, Histopathology.

Cytokine fusion protein treatment.

J. Becker, E. Bröcker, D. Schrama, 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Highly expressed miR-375 is not an intracellular 2 oncogene in Merkel cell polyomavirus-associated 3 Merkel cell carcinoma 4

J. Becker, D. Schrama, A. Zebisch, 2020 .

Lack of correlation between IGFBP7 expression and BRAF mutational status in melanoma.

J. Becker, D. Schrama, Christian Adam, 2010, Journal of Investigative Dermatology.

No evidence for association of HPyV6 or HPyV7 with different skin cancers.

J. Becker, D. Schrama, R. Houben, 2012, Journal of Investigative Dermatology.

Comparative delineation of T cell clonotypes in coexisting syngeneic B16 melanoma

J. Becker, P. Guldberg, J. Zeuthen, 2000, Cancer Immunology, Immunotherapy.

Current and preclinical treatment options for Merkel cell carcinoma

D. Schrama, R. Houben, M. Samimi, 2023, Expert opinion on biological therapy.

IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence

S. Haferkamp, J. Becker, G. Mann, 2010, Cell.